|
Durham, NC – Male Contraceptive Initiative (MCI), a 501(c)(3) non-profit, has provided funding in the amount of $400,000 USD to Sacyl Pharmaceuticals, Inc. to support the development of a novel on-demand, non-hormonal male contraceptive. This most recent grant from Male Contraceptive Initiative reaffirms the organization’s continued commitment to the male contraception research and development community and its ongoing efforts to bring new methods of male contraception to market. “Market research demonstrates that about half of men in the U.S. and even greater proportions of men in select low- and middle-income countries are seeking more options to participate in contraception with their partners. We are confident that the time is right to vigorously support the talent and energy in the field of non-hormonal male contraception, and this grant solidifies our partnership with Sacyl Pharmaceuticals, which exemplifies our vision for a future where family planning is shared by both partners,” said MCI Executive Director Heather Vahdat. “Sacyl Pharmaceuticals is a particularly exciting investment as a potential non-hormonal on-demand method that would provide a very exciting, user-friendly contraceptive option to men who have had to rely on only two methods of birth control for decades: condoms and vasectomy,” Ms. Vahdat added. Sacyl Pharmaceuticals is working towards innovative contraceptive solutions, leveraging the genetically and pharmacologically validated contraceptive target soluble adenylyl cyclase (sAC; ADCY10) into on-demand options for men and women. The male non-hormonal contraceptive that Sacyl Pharmaceuticals is developing is intended to be an on-demand method which temporarily inhibits the ability of sperm to swim as well as blocking their capacity to fertilize, effectively rendering those taking the contraceptive infertile for a short period of time. MCI’s support facilitates the development of novel sAC inhibitors as on-demand contraceptives for men by optimizing the safety and efficacy of new compounds. These steps are crucial to overcome the high bar that will be required of any new contraceptive product. “We are grateful to MCI for their dedication to supporting innovation in male contraception and for recognizing the transformative potential of our work,” said Steve Kretschmer, Sacyl Pharmaceutical’s Chief Executive Officer. “At Sacyl Pharmaceuticals, we are diligently working to meet the needs of people under-served by the existing contraception method mix, and we are very grateful for MCI’s continued support of our mission and vision to reduce unintended pregnancies worldwide.” Sacyl Pharmaceutical’s approach would be ground-breaking: a very fast acting temporary contraceptive pill taken shortly before sex which protects against pregnancy for a defined period of time, and would be retaken whenever needed. “It is critically important that we develop, in parallel, a robust and diverse mix of contraceptive products for men in order to ensure that individual’s unique needs and interests are meaningfully addressed. Sacyl Pharmaceuticals and their potential method represent an exciting opportunity to do just this by providing an on-demand, short-acting, and reversible contraceptive for male users,” said MCI Chief Research Officer Dr. Logan Nickels. With over $14 million invested in product development, MCI seeks to advance male contraceptive research projects to market in order to achieve its organizational vision of “Reproductive Autonomy for All”. MCI’s mission is, “To empower men, and couples, to fully contribute to family planning goals by providing them the resources they need for reproductive autonomy.” About Sacyl Pharmaceuticals, Inc.: Sacyl Pharmaceuticals is a biotech startup in the New York Metropolitan Area that aims to develop potent soluble adenylyl cyclase (sAC) inhibitors into first-in-class systemic, non-hormonal, on-demand contraceptives for men and women with the goal to significantly contribute to increased use of modern contraceptives among couples to reduce unintended pregnancies, improving families’ health and well-being globally. To learn more, please visit: https://www.sacylpharma.com/
About Male Contraceptive Initiative: Male Contraceptive Initiative’s vision is “Reproduction Autonomy for All”, and works to accomplish this by bringing new male contraceptives to market. The non-profit accomplishes this through direct funding, technical support, research, and advocacy. MCI believes that couples deserve options and that they offer the biggest potential impact by focusing on male contraceptives. It’s time men are given more opportunities to contribute toward family planning. To learn more, please visit: https://www.malecontraceptive.org/
0 Comments
|
RSS Feed
